Stoke Therapeutics, Inc.
Financials
Valuation Metrics
Stoke Therapeutics, Inc.'s Market Cap is $1.83B. At end of 2025 it was $1.85B. Ranked #2075 of 3,121 in US market (top 66%), #807 of 1,463 on NASDAQ (top 55%), #146 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 55%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.83B | US#2,075/3,121 Sec#146/266 |
| Revenue | $28M | US#2,812/3,121 Sec#162/266 |
| Net Income | $-208M | US—/3,121 Sec—/266 |
| Total Assets | $394M | US#2,849/3,121 Sec#191/266 |
| Net Assets | $346M | US#2,463/3,121 Sec#151/266 |
| Employees | 170 | US#2,523/3,121 Sec#135/266 |
| Value | ||
| P/B | 5.31x | US#2,286/3,121 Sec#147/266 |
| P/S | 66.50x | US#2,932/3,121 Sec#170/266 |
| FCF Yield | -9.85% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -60.17% | US#2,719/3,121 Sec#172/266 |
| ROA | -52.77% | US#2,999/3,121 Sec#219/266 |
| Op. Margin | -809.69% | US#2,825/3,121 Sec#164/266 |
| Revenue Growth | -86.20% | US#2,767/3,121 Sec#180/266 |
| Earnings Growth | -496.12% | US#2,009/3,121 Sec#67/266 |
| Financial Health | ||
| Debt Ratio | 14.01% | US#160/3,121 Sec#66/266 |
| Total Debt | $3M | US#2,952/3,121 Sec#232/266 |
| FCF | $-181M | US#2,759/3,121 Sec#199/266 |
| Cash | $110M | US#2,176/3,121 Sec#168/266 |
| Current Ratio | 7.69x | US#329/3,121 Sec#102/266 |
| Performance | ||
| 1Y Return | 20.98% | US#979/3,121 Sec#143/266 |
| 1M Return | -13.93% | US#2,430/3,121 Sec#184/266 |
| From 52W High | -29.31% | US#1,959/3,121 Sec#152/266 |
| 1Y MDD | -37.16% | US#1,870/3,121 Sec#130/266 |
| Trading | ||
| Volume | 1,243,952 shares | US#1,447/3,121 Sec#154/266 |
| Trading Value | $35M | US#1,681/3,121 Sec#129/266 |
| Per Share | ||
| EPS | $-3.22 | US—/3,121 Sec—/266 |
| BPS | $5.36 | US#2,259/3,121 Sec#125/266 |
Company Info
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.